OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage currently has a $1.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 8.70% from the stock’s previous close. According to […]
